Therapy for osteosarcoma: Where do we go from here?

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and aggressive surgical resection of all sites of disease involvement. The current national and international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the backbone of cisplatin, doxorubicin, and methotrexate. This protocol is designed to clarify whether (i) the addition of ifosfamide and etoposide to postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a poor histologic response to 10 weeks of preoperative chemotherapy; and (ii) the addition of pegylated interferon-α-2b as maintenance therapy after postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a good histologic response to 10 weeks of preoperative chemotherapy. However, the optimal treatment strategy (or strategies) for patients with relapsed or metastatic disease has yet to be defined. This remains one of the persistent challenges in the treatment of osteosarcoma. Recent therapeutic advances have focused on circumventing chemotherapy resistance mechanisms, incorporation of non-classical agents into upfront therapy, targeting of the tumor micro-environment, and investigating the role of novel delivery mechanisms. In patients with localized disease the 5-year survival rate is at least 70%; patients with metastatic or recurrent disease have <20% chance of long-term survival despite aggressive therapies. These figures have changed little in the past 2 decades. This review focuses on the current therapy for osteosarcoma, and highlights emerging strategies that will hopefully change the outlook for patients with this disease.

Original languageEnglish (US)
Pages (from-to)315-327
Number of pages13
JournalPediatric Drugs
Volume10
Issue number5
DOIs
StatePublished - 2008

Fingerprint

Osteosarcoma
Drug Therapy
Methotrexate
Doxorubicin
Cisplatin
Therapeutics
Disease-Free Survival
Survival
Ifosfamide
Etoposide
Interferons
Neoplasms
Survival Rate
Bone and Bones

Keywords

  • Adolescents
  • Cediranib, therapeutic use
  • Children
  • Cisplatin, therapeutic use
  • Deforolimus, therapeutic use
  • Doxorubicin, therapeutic use
  • Etoposide, therapeutic use
  • Granulocyte macrophage colony stimulating factors, therapeutic use

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology

Cite this

Therapy for osteosarcoma : Where do we go from here? / Chou, Alexander Ja-Ho; Geller, David S.; Gorlick, Richard.

In: Pediatric Drugs, Vol. 10, No. 5, 2008, p. 315-327.

Research output: Contribution to journalArticle

@article{d4bd75e276854cd98479c69b6506638e,
title = "Therapy for osteosarcoma: Where do we go from here?",
abstract = "Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and aggressive surgical resection of all sites of disease involvement. The current national and international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the backbone of cisplatin, doxorubicin, and methotrexate. This protocol is designed to clarify whether (i) the addition of ifosfamide and etoposide to postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a poor histologic response to 10 weeks of preoperative chemotherapy; and (ii) the addition of pegylated interferon-α-2b as maintenance therapy after postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a good histologic response to 10 weeks of preoperative chemotherapy. However, the optimal treatment strategy (or strategies) for patients with relapsed or metastatic disease has yet to be defined. This remains one of the persistent challenges in the treatment of osteosarcoma. Recent therapeutic advances have focused on circumventing chemotherapy resistance mechanisms, incorporation of non-classical agents into upfront therapy, targeting of the tumor micro-environment, and investigating the role of novel delivery mechanisms. In patients with localized disease the 5-year survival rate is at least 70{\%}; patients with metastatic or recurrent disease have <20{\%} chance of long-term survival despite aggressive therapies. These figures have changed little in the past 2 decades. This review focuses on the current therapy for osteosarcoma, and highlights emerging strategies that will hopefully change the outlook for patients with this disease.",
keywords = "Adolescents, Cediranib, therapeutic use, Children, Cisplatin, therapeutic use, Deforolimus, therapeutic use, Doxorubicin, therapeutic use, Etoposide, therapeutic use, Granulocyte macrophage colony stimulating factors, therapeutic use",
author = "Chou, {Alexander Ja-Ho} and Geller, {David S.} and Richard Gorlick",
year = "2008",
doi = "10.2165/00148581-200810050-00005",
language = "English (US)",
volume = "10",
pages = "315--327",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Therapy for osteosarcoma

T2 - Where do we go from here?

AU - Chou, Alexander Ja-Ho

AU - Geller, David S.

AU - Gorlick, Richard

PY - 2008

Y1 - 2008

N2 - Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and aggressive surgical resection of all sites of disease involvement. The current national and international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the backbone of cisplatin, doxorubicin, and methotrexate. This protocol is designed to clarify whether (i) the addition of ifosfamide and etoposide to postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a poor histologic response to 10 weeks of preoperative chemotherapy; and (ii) the addition of pegylated interferon-α-2b as maintenance therapy after postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a good histologic response to 10 weeks of preoperative chemotherapy. However, the optimal treatment strategy (or strategies) for patients with relapsed or metastatic disease has yet to be defined. This remains one of the persistent challenges in the treatment of osteosarcoma. Recent therapeutic advances have focused on circumventing chemotherapy resistance mechanisms, incorporation of non-classical agents into upfront therapy, targeting of the tumor micro-environment, and investigating the role of novel delivery mechanisms. In patients with localized disease the 5-year survival rate is at least 70%; patients with metastatic or recurrent disease have <20% chance of long-term survival despite aggressive therapies. These figures have changed little in the past 2 decades. This review focuses on the current therapy for osteosarcoma, and highlights emerging strategies that will hopefully change the outlook for patients with this disease.

AB - Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and aggressive surgical resection of all sites of disease involvement. The current national and international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the backbone of cisplatin, doxorubicin, and methotrexate. This protocol is designed to clarify whether (i) the addition of ifosfamide and etoposide to postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a poor histologic response to 10 weeks of preoperative chemotherapy; and (ii) the addition of pegylated interferon-α-2b as maintenance therapy after postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a good histologic response to 10 weeks of preoperative chemotherapy. However, the optimal treatment strategy (or strategies) for patients with relapsed or metastatic disease has yet to be defined. This remains one of the persistent challenges in the treatment of osteosarcoma. Recent therapeutic advances have focused on circumventing chemotherapy resistance mechanisms, incorporation of non-classical agents into upfront therapy, targeting of the tumor micro-environment, and investigating the role of novel delivery mechanisms. In patients with localized disease the 5-year survival rate is at least 70%; patients with metastatic or recurrent disease have <20% chance of long-term survival despite aggressive therapies. These figures have changed little in the past 2 decades. This review focuses on the current therapy for osteosarcoma, and highlights emerging strategies that will hopefully change the outlook for patients with this disease.

KW - Adolescents

KW - Cediranib, therapeutic use

KW - Children

KW - Cisplatin, therapeutic use

KW - Deforolimus, therapeutic use

KW - Doxorubicin, therapeutic use

KW - Etoposide, therapeutic use

KW - Granulocyte macrophage colony stimulating factors, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=50649107280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649107280&partnerID=8YFLogxK

U2 - 10.2165/00148581-200810050-00005

DO - 10.2165/00148581-200810050-00005

M3 - Article

C2 - 18754698

AN - SCOPUS:50649107280

VL - 10

SP - 315

EP - 327

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 5

ER -